Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 4/20 | 0.57 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.57 |
| ▸ | ENPP2 | Q13822 | 7/20 | 0.56 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.43 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL692342 | 0.87 | ENPP2 (0.67) | LPLLIPGENPP2KDM4EALDH1A1 | |
| SCHEMBL5872608 | 0.87 | ENPP2 (0.72) | LPLLIPGENPP2KDM4EALDH1A1 | |
| SCHEMBL14858240 | 0.85 | ENPP2 (0.64) | LPLLIPGENPP2KDM4EALDH1A1 | |
| SCHEMBL2563101 | 0.82 | ENPP2 (0.56) | LPLLIPGENPP2KDM4EALDH1A1 | |
| SCHEMBL2555065 | 0.79 | ENPP2 (0.71) | LPLLIPGENPP2TP53 | |
| SCHEMBL3132606 | 0.79 | ENPP2 (0.56) | LPLLIPGENPP2KDM4EALDH1A1 | |
| SCHEMBL3792599 | 0.79 | MGLL (0.63) | LPLLIPGENPP2KDM4EALDH1A1 | |
| SCHEMBL5671549 | 0.78 | TP53 (0.52) | LPLLIPGSLC5A2SLC5A1ALDH1A1 | |
| SCHEMBL8087587 | 0.76 | CYP1A2 (0.48) | SLC5A2SLC5A1ALDH1A1MGLLTP53 | |
| SCHEMBL18466196 | 0.76 | ENPP2 (0.50) | ENPP2SLC5A2SLC5A1KDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048897-B2 | Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-11-01 | — | — | US | disclosed |
| US-20080318874-A1 | Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-12-25 | — | — | US | disclosed |
| EP-1783110-A1 | NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318874-A1 | Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes | SLC5A1, GPR119, SLC5A2 | LPL 2018/4885LIPG 2491/4885ENPP2 2976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.